Interleukin-1 family expression in human breast cancer: Interleukin-1 receptor antagonist
Interleukin-1 family expression in human breast cancer: Interleukin-1 receptor antagonist
复制标题
DOI：
10.3109/07357900009012171
复制
发表时间：
2000-01-01
影响因子：
2.4
通讯作者：
Kreutzer, DL
中科院分区：
文献类型：
--
作者：
Miller, LJ;Kurtzman, SH;Kreutzer, DL
我们假设白细胞介素-1 α、β和受体拮抗剂（分别为IL-1 α、IL-1 β和IL-1 ra）存在于人乳腺癌（HBC）中并与肿瘤细胞相关。我们相信这些细胞因子在乳腺肿瘤匀浆中的水平与其他已知的患者存活率的决定因素有关（即，雌激素受体[ER]状态）。我们的研究结果表明，在化学上，肿瘤细胞表达IL-1 α，IL-1 β和IL-1 ra在大多数标本测试。在乳腺组织匀浆中，IL-1 α水平与ER水平呈负相关（p < 0.06），而IL-1 ra水平与ER水平（p < 0.009）和IL-1 β水平（p < 0.06）均呈正相关。当分析ER（-）与ER（+）患者组的细胞因子水平时，我们发现在许多情况下这些组显示出不同的细胞因子谱。这些研究表明，IL-1家族的细胞因子可能是重要的，在调节HBC肿瘤微环境内的促肿瘤活性。
We hypothesize that interleukin-1 alpha, beta, and receptor antagonist (IL-1 alpha, IL-1 beta, and IL-1ra, respectively) are present and tumor cell associated in human breast cancer (HBC). We believe the levels of these cytokines in breast tumor homogenates relate to other known prognosticators of patient survival (i.e., estrogen receptor [ER] status). Our results demonstrated that, immunohistochemically, tumor cells express IL-1 alpha, IL-1 beta, and IL-1ra in most specimens tested. In breast tissue homogenates, IL-1 alpha levels correlated inversely with ER levels (p < 0.06), whereas IL-1ra levels correlated directly with both ER levels (p < 0.009) and IL-1 beta levels (p < 0.06). When analyzing cytokine levels for the ER (-) versus ER (+) patient groups, we found that in many instances these groups showed a different cytokine profile. These studies suggest that the IL-1 family of cytokines may be important in regulating protumorigenic activities within the HBC tumor microenvironment.